Positive results from the trial phase of the Code 19 vaccine

In the first and second trials of the Russian vaccine, all 76 people in the study developed antibodies. According to the study, 50% reported fever, 42% headache, 28% weakness and 24% joint pain. The vaccine will be tested on 40,000 volunteers in the third phase. Russia claimed the world's first approved corona virus vaccine for public use in August, before the third phase of the trial was completed, which drew strong criticism.